Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference.

Lobitz S, Telfer P, Cela E, Allaf B, Angastiniotis M, Backman Johansson C, Badens C, Bento C, Bouva MJ, Canatan D, Charlton M, Coppinger C, Daniel Y, de Montalembert M, Ducoroy P, Dulin E, Fingerhut R, Frömmel C, García-Morin M, Gulbis B, Holtkamp U, Inusa B, James J, Kleanthous M, Klein J, Kunz JB, Langabeer L, Lapouméroulie C, Marcao A, Marín Soria JL, McMahon C, Ohene-Frempong K, Périni JM, Piel FB, Russo G, Sainati L, Schmugge M, Streetly A, Tshilolo L, Turner C, Venturelli D, Vilarinho L, Yahyaoui R, Elion J, Colombatti R; with the endorsement of EuroBloodNet, the European Reference Network in Rare Haematological Diseases.

Br J Haematol. 2018 Nov;183(4):648-660. doi: 10.1111/bjh.15600. Epub 2018 Oct 18.

PMID:
30334577
2.

Reliability of the current newborn screening action value for beta thalassaemia disease detection in England: A prospective study.

Daniel Y, Henthorn J.

J Med Screen. 2019 Jun;26(2):67-70. doi: 10.1177/0969141318797373. Epub 2018 Sep 24.

PMID:
30249157
3.

Sickle-Cell Disease in Nigerian Children: Parental Knowledge and Laboratory Results.

Obaro SK, Daniel Y, Lawson JO, Hsu WW, Dada J, Essen U, Ibrahim K, Akindele A, Brooks K, Olanipekun G, Ajose T, Stewart CE, Inusa BP.

Public Health Genomics. 2016;19(2):102-7. doi: 10.1159/000444475. Epub 2016 Mar 19.

PMID:
26991896
4.
5.

Evaluation of the validity of Hb A2 and mean corpuscular haemoglobin action values in antenatal screening for beta thalassaemia carriers in England.

Daniel Y, Cartwright R, Rennie K, Streetly A, Howard J.

Br J Haematol. 2014 Aug;166(4):607-11. doi: 10.1111/bjh.12917. Epub 2014 Apr 23.

PMID:
24754789
6.

Newborn bloodspot results: predictive value of screen positive test for thalassaemia major.

Streetly A, Latinovic R, Henthorn J, Daniel Y, Dormandy E, Darbyshire P, Mantio D, Fraser L, Farrar L, Will A, Tetlow L.

J Med Screen. 2013 Dec;20(4):183-7. doi: 10.1177/0969141313514217. Epub 2013 Nov 25.

PMID:
24277229
7.

Sickle cell/β0-thalassemia associated with the 1393 bp deletion can be associated with a severe phenotype.

Daniel Y, Hill K, Inusa B, Thein SL, Howard J.

Hemoglobin. 2011;35(4):406-10. doi: 10.3109/03630269.2011.592555.

PMID:
21797706
8.

Newborn screening for sickle cell disease through use of tandem mass spectrometry.

Turner C, Daniel Y, Dalton RN.

Clin Chem. 2009 Jun;55(6):1243-4; author reply 1244-5. doi: 10.1373/clinchem.2008.120964. Epub 2009 Apr 2. No abstract available.

9.

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA.

Br J Haematol. 2008 Apr;141(1):41-51. doi: 10.1111/j.1365-2141.2008.07013.x.

PMID:
18324965
10.

The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease.

Vasavda N, Menzel S, Kondaveeti S, Maytham E, Awogbade M, Bannister S, Cunningham J, Eichholz A, Daniel Y, Okpala I, Fulford T, Thein SL.

Br J Haematol. 2007 Jul;138(2):263-70.

PMID:
17593033
11.

Quantification of hemoglobin A2 by tandem mass spectrometry.

Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN.

Clin Chem. 2007 Aug;53(8):1448-54. Epub 2007 Jun 7.

12.

Rapid and specific detection of clinically significant haemoglobinopathies using electrospray mass spectrometry-mass spectrometry.

Daniel YA, Turner C, Haynes RM, Hunt BJ, Dalton RN.

Br J Haematol. 2005 Aug;130(4):635-43.

PMID:
16098080
13.

Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells.

Okpala I, Daniel Y, Haynes R, Odoemene D, Goldman J.

Eur J Haematol. 2002 Sep;69(3):135-44.

PMID:
12406006

Supplemental Content

Loading ...
Support Center